TY  - JOUR
A1  - Sagiv, Jitka Y.
A1  - Michaeli, Janna
A1  - Assi, Simaan
A1  - Mishalian, Inbal
A1  - Kisos, Hen
A1  - Levy, Liran
A1  - Damti, Pazzit
A1  - Lumbroso, Delphine
A1  - Polyansky, Lola
A1  - Sionov, Ronit V.
A1  - Ariel, Amiram
A1  - Hovav, Avi-Hai
A1  - Henke, Erik
A1  - Fridlender, Zvi G.
A1  - Granot, Zvi
T1  - Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer
JF  - Cell Reports
N2  - Controversy surrounds neutrophil function in cancer because neutrophils were shown to provide both pro-and antitumor functions. We identified a heterogeneous subset of low-density neutrophils (LDNs) that appear transiently in self-resolving inflammation but accumulate continuously with cancer progression. LDNs display impaired neutrophil function and immunosuppressive properties, characteristics that are in stark contrast to those of mature, high-density neutrophils (HDNs). LDNs consist of both immature myeloid-derived suppressor cells (MDSCs) and mature cells that are derived from HDNs in a TGF-beta-dependent mechanism. Our findings identify three distinct populations of circulating neutrophils and challenge the concept that mature neutrophils have limited plasticity. Furthermore, our findings provide a mechanistic explanation to mitigate the controversy surrounding neutrophil function in cancer.
KW  - tumorigenic properties
KW  - innate immunity
KW  - adenocarcinoma
KW  - inhibition
KW  - model
KW  - suppressor cells
KW  - tumor
KW  - TGF-beta
KW  - mice
KW  - lung
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-144102
VL  - 10
IS  - 4
ER  - 
TY  - JOUR
A1  - Lv, Xiaoqun
A1  - Zhang, Lingyun
A1  - Zhu, Yanyan
A1  - Said, Harun M.
A1  - Shi, Jimin
A1  - Xu, Guoxiong
T1  - Regulative effect of Nampt on tumor progression and cell viability in human colorectal cancer
JF  - Journal of Cancer
N2  - Colorectal cancer (CRC) is the third most common cancer disease. Here we examined Nampt expression in patients with CRC and the effect of Nampt on cell viability in CRC cells. Nampt protein was overexpressed in colorectal adenoma as well as colorectal carcinoma. The immunoreactive staining of Nampt was negative in the adjacent normal colorectal tissue, weak in colorectal adenoma, and strong in colorectal carcinoma, which may represent tumor progression. Further evaluation of clinical data showed that Nampt expression was not correlated with the clinicopathological characteristics of CRC. Additionally, our in vitro studies demonstrated that Nampt promotes CRC cell viability, whereas the Nampt inhibitor FK866 suppressed CRC cell viability, which was in concordance with the previous studies in other cancer cells. Treatment with Nampt-siRNA reduced the Nampt protein expression resulting in the inhibition of the cell viability of HCT116 and Caco2. Thus, the involvement of Nampt in cell growth indicates that Nampt may play an important role in colorectal tumorigenesis. As a consequence, our results suggest that Nampt may be considered as a progression marker of colorectal tumor and a potentially therapeutic target for the treatment of CRC.
KW  - nicotinamide phosphoribosyltransferase
KW  - signaling pathways
KW  - gastric cancer
KW  - overexpression
KW  - cell proliferation
KW  - tumor biomarker
KW  - adenocarcinoma
KW  - Nampt
KW  - visfatin
KW  - PBEF
KW  - breast cancer
KW  - prognostic value
KW  - visfatin levels
KW  - inhibitor
KW  - expression
KW  - adipocytokines
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-144516
VL  - 6
IS  - 9
ER  -